Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07532473

REal World MAIA UK OutcomEs

Conditions: Myeloma

Sex: All

Ages: 18 Years – N/A

Enrollment: 300

Sponsor: The Royal Wolverhampton Hospitals NHS Trust

Location: The Royal Wolverhampton NHS Trust Wolverhampton

Summary

This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Diagnosis of NDMM * Not eligible for autologous stem cell transplant at diagnosis * Received frontline DRd treatment following NICE approval (post-September 2023) * Minimum 3 months of follow-up data available Exclusion Criteria: * Participation in an interventional clinical trial for first-line therapy * Insufficient treatment or follow-up data for analysis * DRd used in relapsed/refractory setting rather than newly diagnosed disease

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07532473). StuddyBuddy aggregates publicly available trial information.